课题基金 / 基金详情

项目摘要

项目成果

MARINA N PROTOPOPOVA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):结核病(TB)对全球健康有巨大影响。世界卫生组织估计,全球三分之一的人患有潜在的结核病感染,每年有1600万活动性疾病病例和近200万人死于结核分枝杆菌(MTB)。结核病感染是异质性的,目前的药物对所有结核分枝杆菌的效果并不一样。补充结核病治疗武器库的努力远远落后于不断增长的需求,特别是对耐多药或广泛耐药结核病患者。在细菌中,许多对环境线索的关键反应都是由蛋白质对执行的,这些蛋白质对包括一个传感器激酶,它在组氨酸上自动磷酸化,然后将磷酸转移到其同源反应调节蛋白上的天冬氨酸。MTB的组氨酸-天冬氨酸磷酸传递系统是潜在的有吸引力的药物靶点,主要原因有两个:首先,在MTB的两组分系统中,至少有一个MtrAB是即使在丰富的介质中也是生存所必需的,而其他系统在体内的毒力或持久性方面发挥着关键作用。其次,反应调节子上的磷受体位点之间高度保守,而哺乳动物中没有这种蛋白,这表明开发泛特异性和无毒的抑制剂是可能的。我们的策略是在这里专注于MTB的一个重要的2CR,MtrAB,并针对反应调节器而不是在激酶内的信号,克服在处理其他细菌的2CR时遇到的问题。除了靶点验证,我们的工作预计将生产至少一种适合扩展为临床前先导化合物的化学支架。未来的计划将把靶标扩大到分枝杆菌2CR反应调节子这个更大的家族。具体地说,在这项概念验证工作中,我们计划:具体目标1.开发一种基本的MTB 2CR MtrAB抑制剂的分析方法,并将其格式化用于HTS。我们计划采用一种创新的体外磷酸转移试验,合成一组候选报告底物,并对它们进行评估。将选择一个报告底物进行特定目的2.特定目的2.执行MtrAB磷酸转移高通量筛选(HTS)。使用选择的合成报告底物,我们将对100,000个化合物库进行HTS,其中包括从Sequella收藏和麦克马斯特大学的HTS设施获得的化合物。预计命中率约为0.1%-0.2%,从而为特定目标3.3提供100-200个新结构。3.优先选择并扩展特定目标2的命中支架。我们将选择最有希望的结构并进行体外二次筛选。有限的药物化学扩展将产生2-3个不同的支架,适合在随后的研究阶段进行研究。 公共卫生相关性:结核病对全球健康有巨大影响,补充结核病治疗武器库的努力远远落后于不断增长的需求,特别是对耐多药或广泛耐药结核病患者。我们选择了一个有希望的新药靶点,并建议开发一种筛选方法来寻找具有显著潜力的分子,作为治疗结核病、耐多药结核病和广泛耐药结核病的新药候选。
英文摘要
DESCRIPTION (provided by applicant): Tuberculosis (TB) has a massive impact on global health. The World Health Organization estimates that one- third of all people worldwide harbor latent TB infections, with sixteen million cases of active disease and nearly two million deaths caused by Mycobacterium tuberculosis (MTB) each year. TB infections are heterogeneous, and current medicines do not work equally well on all MTB bacteria. Efforts to replenish the TB treatment arsenal lag far behind the growing need, particularly for patients with multi- (MDR) or extensively- (XDR) drug-resistant-TB. In bacteria, many critical responses to environmental cues are performed by protein pairs comprised of a sensor kinase that auto-phosphorylates on a histidine and then transfers this phosphate to an aspartate on its cognate response regulator protein. The MTB histidine-aspartate phosphorelay systems are potentially attractive drug targets for two major reasons: First, of the two-component systems in MTB, at least one, MtrAB, is essential for viability even in rich media while others play key roles in virulence or persistence in vivo. Second, the high conservation among phosphoacceptor sites on the response regulators, and the absence of such proteins in mammals, suggest that developing pan-specific and non-toxic inhibitors may be possible. Our strategy is to focus here on the one essential 2CR of MTB, MtrAB, and target the signaling to the response regulator rather than within the kinase, overcoming problems encountered in approaches with 2CRs of other bacteria. In addition to target validation, our work is anticipated to produce at least one chemical scaffold suitable for expansion into a preclinical lead compound. Future plans will expand the targets to the larger family of mycobacterial 2CR response regulators. Specifically in this proof-of-concept work we plan to: Specific Aim 1. Develop an assay for inhibitors of the essential MTB 2CR MtrAB, and format it for HTS. We plan to adapt an innovative in vitro phospho-transfer assay, synthesize a panel of candidate reporter substrates, and evaluate them. One reporter substrate will be selected to conduct Specific Aim 2. Specific Aim 2. Execute an MtrAB phospho-transfer high-throughput screen (HTS). Using the selected synthetic reporter substrate we will conduct an HTS on a 100,000 compound library comprised of compounds obtained from both the Sequella collection and from McMaster University's HTS facility. An anticipated hit rate of ca 0.1 -0.2 % is anticipated, thus providing 100-200 novel structures for Specific Aim 3. 3. Prioritize and expand hit scaffolds from Specific Aim 2. We will select the most promising structures and run in vitro secondary screens. A limited medicinal chemistry expansion will then produce 2-3 distinct scaffolds suitable for pursuit in a subsequent research phase. PUBLIC HEALTH RELEVANCE: Tuberculosis (TB) has a massive impact on global health, and efforts to replenish the TB treatment arsenal lag far behind the growing need, particularly for patients with multi- (MDR) or extensively- (XDR) drug-resistant-TB. We have chosen a promising new drug target, and propose to develop a screening method to identify molecules with significant potential as new drug candidates for the treatment of TB, MDR-TB, and XDR-TB.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting MtrAB of M. tuberculosis
  • 批准号:
    8124205
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection
  • 批准号:
    8248700
  • 项目类别:
  • 资助金额:
    $80.64万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection
  • 批准号:
    8444472
  • 项目类别:
  • 资助金额:
    $72.58万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
Development of a New Diamine (SQ109) for the Treatment of C. difficile Infection
  • 批准号:
    8634012
  • 项目类别:
  • 资助金额:
    $72.53万
  • 财政年份:
    2011
  • 负责人:
    MARINA N PROTOPOPOVA
  • 依托单位:
国内基金
海外基金
Segmented Filamentous Bacteria激活宿主免疫系统抑制其拮抗菌 Enterobacteriaceae维持菌群平衡及其机制研究
  • 批准号:
    81971557
  • 项目类别:
    面上项目
  • 资助金额:
    65.0万元
  • 批准年份:
    2019
  • 负责人:
    毛开睿
  • 依托单位:
电缆细菌(Cable bacteria)对水体沉积物有机污染的响应与调控机制